Anti-SLC37A4 Polyclonal Antibody for WB, IHC-P, ELISA - O43826

Core Product Specifications and Parameters

Biological Background: SLC37A4 Function and Localization

• SLC37A4 (solute carrier family 37 member 4), also known as glucose-6-phosphate translocase (G6PT), is a glucose-6-phosphate (G6P) exchanger located in the endoplasmic reticulum membrane.
• It functions as an obligatory antiporter, transporting cytoplasmic G6P into the ER lumen while moving inorganic phosphate (Pi) in the opposite direction, a reaction essential for the terminal steps of gluconeogenesis and glycogenolysis. Related references: PMID:10026167, PMID:21949678, PMID:33964207, PMID:41136424, PMID:41225049
• This transport activity is central to blood glucose homeostasis; mutations in SLC37A4 lead to glycogen storage disease type 1b (GSD1b) and related congenital disorders of glycosylation.
• SLC37A4 belongs to the sugar-phosphate transporter family within the major facilitator superfamily, and alternative splicing generates multiple transcript variants.
• Tissue expression is highest in liver and kidney, the primary sites of gluconeogenesis, but it is also present in other tissues.
• The protein is predicted to span the ER membrane several times (transmembrane helices), and its function is critical for both metabolic and glycosylation pathways.
• Keywords associated with this protein include: alternative splicing, congenital disorder of glycosylation, disease variant, glycogen storage disease, membrane, sugar transport, and transmembrane helix.

Experimental Guidance and Technical Tips

• The immunogen used to generate this antibody spans amino acids 330–429 in the C‑terminal region of human SLC37A4, a segment distinct from the predicted transmembrane domains; this design may favor recognition of the native protein.
• Because this is a polyclonal antibody, lot‑to‑lot consistency should be verified by the end user in their specific assay conditions.
• For Western blot, a band near 46 kDa (or possibly around the calculated molecular weight of 46.3 kDa) is expected; validate with appropriate positive and negative controls (e.g., liver or kidney lysates).
• For IHC‑P, signal may be weak due to low expression; consider antigen retrieval and signal amplification, and validate staining in tissues known to express SLC37A4 (liver, kidney).
• In ELISA, peptide‑based coating may be used; cross‑reactivity with mouse and rat suggests the antibody may recognize orthologous proteins, but sequence alignment of the immunogen region is recommended.
• As with any research reagent, this antibody is not intended for diagnostic or therapeutic procedures.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers a comprehensive one-stop sourcing solution for IVD raw materials, from validated antibody pairs to bulk ancillary reagents. This anti‑SLC37A4 polyclonal antibody supports glucose homeostasis and glycogen storage disease research, and we can assist with custom antibody development and technical consulting for your diagnostic pipeline. Contact our team to discuss your specific sourcing needs.